Psoriasis diagnoses in Brazil's public health system grew 19.2% annually from 2019-2024, triple the pre-2019 rate, affecting skin, joints, nails and overall quality of life. Red plaques, nail changes, joint pain and itching are key symptoms; stress, infections, cold weather and certain medications trigger flare-ups in genetically predisposed individuals.
CartaCapital
· Jun 02, 2026
· health
· 4 min de leitura
High
Apuração: Verificado
Psoríase: novos tratamentos transformam manejo da doença inflamatória crônica
Psoriasis impacts emotional wellbeing, sleep quality, self-esteem and productivity in millions of patients, with women experiencing delayed diagnoses compared to men.
◉
Health & Medicine
2808 artigos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% correspondência
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% correspondência
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% correspondência
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% correspondência
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% correspondência
Cobertura Relacionada
Diário de Petrópolis · Aug 24
Dengue, zika, chikungunya e Oropouche: diferenças e riscos da automedicação
Arboviroses apresentam sintomas semelhantes mas evoluções distintas; automedicação com anti-inflamatórios pode agravar d…
ZAP Notícias · Aug 23 Proximidade de lavandarias a seco pode aumentar risco de ParkinsonEstudo com dados de Medicare sugere que viver a menos de 152 metros de lavandarias a seco está associado a 14% maior pro…
TVBV ONLINE · Aug 23 Uso inadequado de zolpidem acende alerta sobre riscos do remédio para insôniaEspecialistas alertam sobre riscos do zolpidem, medicamento popular para insônia no Brasil, que pode causar dependência …
en.com.br · Aug 23 Calor extremo em Cuiabá aumenta risco de pedra nos rins sem hidratação adequadaAltas temperaturas em Cuiabá favorecem desidratação e aumentam concentração de substâncias na urina, elevando o risco de…
Viés e Enquadramento
⚖
Article presents medical information on psoriasis treatments with institutional sources; minimal apparent bias but relies heavily on pharmaceutical industry data and expert credentials from medical education company.
Bias Direction
center-right
Confidence
MED
Medical authority framing combined with pharmaceutical industry-friendly narrative. Article emphasizes new drug approval and market research data (Ipsos) showing disease growth, positioning pharmaceutical solutions as primary response to health challenge.
reacendeu o debate (reignited debate - suggests renewed urgency)
cenário também chama atenção (scenario also draws attention - implies concern)
crescimento expressivo (expressive/notable growth - emphasizes magnitude)
índices praticamente triplicaram (indices practically tripled - strong language emphasizing acceleration)
Patient voices and lived experiences with psoriasis
Cost-benefit analysis or affordability concerns for new medications
Alternative or complementary treatment approaches
Perspectives from public health officials on SUS capacity
Critical analysis of why diagnoses tripled (improved detection vs. actual disease increase)
Potential side effects or limitations of biologic treatments
Dermatologists without pharmaceutical company affiliations
Impacto Geopolítico
🌎
Brazilian health article on psoriasis treatment advances; no geopolitical implications detected.
Escalation Risk
low
Confidence
HIGH
Lente Econômica
📈
Brazil's psoriasis diagnoses tripled since 2019 with new biologic medications approved, expanding treatment options for 125M global patients and driving growth in pharmaceutical and healthcare sectors.
Market Signal
bullish
Confidence
HIGH
Pharmaceuticals & Biopharmaceuticals
Healthcare Services
Public Health (SUS)
Medical Devices
Dermatology Specialty Care
Patients gain access to improved biologic treatments with better outcomes, though affordability and SUS coverage expansion will determine accessibility for lower-income Brazilians. Increased diagnoses may reduce undiagnosed cases but increase treatment costs for households and public health system.
SUS budget pressures likely as treatment volume grows 25% annually; potential need for expanded pharmaceutical coverage policies. Anvisa approval acceleration suggests regulatory support for innovative therapies. Government may need to negotiate drug pricing and establish treatment guidelines for cost management.